Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233


The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.


Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Jun;98(6):839. doi: 10.1038/s41374-018-0037-4.


Clinical implications of PTEN loss in prostate cancer.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL.

Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review.


Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Apr;98(4):403-413. doi: 10.1038/s41374-017-0007-2. Epub 2018 Jan 16. Review. Erratum in: Lab Invest. 2018 Mar 8;:.


Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer.

Vidotto T, Tiezzi DG, Squire JA.

Mol Cytogenet. 2018 Jan 3;11:1. doi: 10.1186/s13039-017-0348-y. eCollection 2018.


Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome.

Josahkian JA, Saggioro FP, Vidotto T, Ventura HT, Candido Dos Reis FJ, de Sousa CB, Tiezzi DG, de Andrade JM, Koti M, Squire JA.

Int J Gynecol Cancer. 2018 Mar;28(3):459-465. doi: 10.1097/IGC.0000000000001193.


Complex Mosaic Ring Chromosome 11 Associated with Hemizygous Loss of 8.6 Mb of 11q24.2qter in Atypical Jacobsen Syndrome.

Galvão Gomes A, Paiva Grangeiro CH, Silva LR, Oliveira-Gennaro FG, Pereira CS, Joaquim TM, Panepucci RA, Squire JA, Martelli L.

Mol Syndromol. 2017 Jan;8(1):45-49. doi: 10.1159/000452681. Epub 2016 Nov 17.


STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.

Au KK, Le Page C, Ren R, Meunier L, Clément I, Tyrishkin K, Peterson N, Kendall-Dupont J, Childs T, Francis JA, Graham CH, Craig AW, Squire JA, Mes-Masson AM, Koti M.

J Pathol Clin Res. 2016 Sep 19;2(4):259-270. eCollection 2016 Oct.


Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L, Hurtado-Coll A, McKenney JK, Simko J, Carroll PR, Gleave M, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Lance R, Troyer D, Squire JA.

Mod Pathol. 2016 Aug;29(8):904-14. doi: 10.1038/modpathol.2016.88. Epub 2016 May 13.


Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.

Nawaz M, Fatima F, Nazarenko I, Ekström K, Murtaza I, Anees M, Sultan A, Neder L, Camussi G, Valadi H, Squire JA, Kislinger T.

Expert Rev Proteomics. 2016;13(4):395-409. doi: 10.1586/14789450.2016.1165613. Review.


In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

Picanço-Albuquerque CG, Morais CL, Carvalho FL, Peskoe SB, Hicks JL, Ludkovski O, Vidotto T, Fedor H, Humphreys E, Han M, Platz EA, De Marzo AM, Berman DM, Lotan TL, Squire JA.

Virchows Arch. 2016 May;468(5):607-17. doi: 10.1007/s00428-016-1904-2. Epub 2016 Feb 9.


First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.

Weberpals JI, Amin MS, Chen BE, Tu D, Spaans JN, Squire JA, Eisenhauer EA, Virk S, Ma D, Duciaume M, Hoskins P, LeBrun DP.

Gynecol Oncol. 2016 Mar;140(3):486-93. doi: 10.1016/j.ygyno.2016.01.015. Epub 2016 Jan 13.


Lacrimal gland anaplastic kinase-positive large B-cell lymphoma (LBCL-ALK+) with an atypical clinical presentation.

Duarte AF, Squire JA, Chahud F, Cruz AA.

Clin Exp Ophthalmol. 2016 Aug;44(6):520-2. doi: 10.1111/ceo.12702. Epub 2016 Feb 11. No abstract available.


A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.459. No abstract available.


Extracellular Vesicles: Evolving Factors in Stem Cell Biology.

Nawaz M, Fatima F, Vallabhaneni KC, Penfornis P, Valadi H, Ekström K, Kholia S, Whitt JD, Fernandes JD, Pochampally R, Squire JA, Camussi G.

Stem Cells Int. 2016;2016:1073140. doi: 10.1155/2016/1073140. Epub 2015 Nov 16. Review.


Current state of biomarkers in ovarian cancer prognosis.

Au KK, Josahkian JA, Francis JA, Squire JA, Koti M.

Future Oncol. 2015;11(23):3187-95. doi: 10.2217/fon.15.251. Epub 2015 Nov 9. Review.


A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.

Invest New Drugs. 2015 Aug;33(4):969-76. doi: 10.1007/s10637-015-0252-4. Epub 2015 May 19.


A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.

Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA.

Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4.


A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Mar 31;112(7):1215-22. doi: 10.1038/bjc.2015.81. Erratum in: Br J Cancer. 2015 Dec 22;113(12):1746. Masson, A-M M [corrected to Mes-Masson, A-M].


ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR.

Clin Cancer Res. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9.


Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.

Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, Bayani J, Pressey JC, Lionel AC, Clarke ID, Cusimano M, Squire JA, Scherer SW, Bernstein M, Woodin MA, Bader GD, Dirks PB.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):851-6. doi: 10.1073/pnas.1320611111. Epub 2015 Jan 5.


Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.

Lancet Oncol. 2014 Dec;15(13):1521-32. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13.


Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.

Williams JL, Greer PA, Squire JA.

Cancer Genet. 2014 Oct-Dec;207(10-12):474-88. doi: 10.1016/j.cancergen.2014.09.003. Epub 2014 Sep 16.


Composite mantle cell and primary cutaneous anaplastic large cell lymphoma: case report and review of the literature.

Leduc C, Blandino II, Alhejaily A, Baetz T, Good DJ, Farmer PL, Squire JA, LeBrun DP.

Am J Dermatopathol. 2015 Mar;37(3):232-6. doi: 10.1097/DAD.0000000000000233. Review.


Smoking-induced chromosomal segregation anomalies identified by FISH analysis of sperm.

Pereira CS, Juchniuk de Vozzi MS, Dos Santos SA, Vasconcelos MA, de Paz CC, Squire JA, Martelli L.

Mol Cytogenet. 2014 Sep 12;7(1):58. doi: 10.1186/s13039-014-0058-7. eCollection 2014.


PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.

Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor H, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM.

Mod Pathol. 2015 Jan;28(1):128-137. doi: 10.1038/modpathol.2014.85. Epub 2014 Jul 4.


Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.

Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M.

PLoS One. 2014 May 16;9(5):e95843. doi: 10.1371/journal.pone.0095843. eCollection 2014.


Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.


MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.

van der Deen M, Taipaleenmäki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, Shogren K, Maran A, Yaszemski MJ, Ling L, Cool SM, Leong DT, Dierkes C, Zustin J, Salto-Tellez M, Ito Y, Bae SC, Zielenska M, Squire JA, Lian JB, Stein JL, Zambetti GP, Jones SN, Galindo M, Hesse E, Stein GS, van Wijnen AJ.

J Biol Chem. 2013 Jul 19;288(29):21307-19. doi: 10.1074/jbc.M112.445890. Epub 2013 May 29.


Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance.

Oros KK, Arcand SL, Bayani J, Squire JA, Mes-Masson AM, Tonin PN, Greenwood CM.

Cancer Genet. 2013 Apr;206(4):103-15. doi: 10.1016/j.cancergen.2013.03.001. Epub 2013 Apr 25. Review.


Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.

Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN, Vanderhyden BC.

Orphanet J Rare Dis. 2013 Feb 21;8:33. doi: 10.1186/1750-1172-8-33.


The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression.

Choucair KA, Guérard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J.

Transl Oncol. 2012 Dec;5(6):453-60. Epub 2012 Dec 1.


Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression.

Bayani J, Kuzmanov U, Saraon P, Fung WA, Soosaipillai A, Squire JA, Diamandis EP.

Clin Chem. 2013 Jan;59(1):296-305. doi: 10.1373/clinchem.2012.193060. Epub 2012 Nov 7.


PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ.

Mod Pathol. 2013 Mar;26(3):435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.


Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma.

Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H, Pasic M, Yousef GM.

Cancer Res. 2012 Oct 15;72(20):5273-84. doi: 10.1158/0008-5472.CAN-12-0656. Epub 2012 Aug 27.


The genetics of osteosarcoma.

Martin JW, Squire JA, Zielenska M.

Sarcoma. 2012;2012:627254. doi: 10.1155/2012/627254. Epub 2012 May 20.


Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor.

Li M, Lockwood W, Zielenska M, Northcott P, Ra YS, Bouffet E, Yoshimoto M, Rutka JT, Yan H, Taylor MD, Eberhart C, Hawkins CE, Lam W, Squire JA, Huang A.

Cancer Genet. 2012 May;205(5):220-31. doi: 10.1016/j.cancergen.2012.03.002.


A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.

Pedeutour F, Maire G, Pierron A, Thomas DM, Garsed DW, Bianchini L, Duranton-Tanneur V, Cortes-Maurel A, Italiano A, Squire JA, Coindre JM.

Virchows Arch. 2012 Jul;461(1):67-78. doi: 10.1007/s00428-012-1256-5. Epub 2012 Jun 8.


Karyotype/phenotype correlation in partial trisomies of the long arm of chromosome 16: case report and review of literature.

Laus AC, Baratela WA, Laureano LA, Santos SA, Huber J, Ramos ES, Rebelo CC, Squire JA, Martelli L.

Am J Med Genet A. 2012 Apr;158A(4):821-7. doi: 10.1002/ajmg.a.32988. Epub 2012 Feb 21. Review.


Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.

Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG.

Cancer. 2012 Aug 15;118(16):4053-62. doi: 10.1002/cncr.26729. Epub 2012 Jan 26. Erratum in: Cancer. 2014 Aug 1;120(15):2380. Jurisca, Igor [corrected to Jurisica, Igor].


Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA.

Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.


Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.

Weberpals JI, Koti M, Squire JA.

Cancer Genet. 2011 Oct;204(10):525-35. doi: 10.1016/j.cancergen.2011.09.004. Review.


Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression.

Smith AC, Suzuki M, Thompson R, Choufani S, Higgins MJ, Chiu IW, Squire JA, Greally JM, Weksberg R.

Genomics. 2012 Jan;99(1):25-35. doi: 10.1016/j.ygeno.2011.10.007. Epub 2011 Nov 3.


NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.

Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, van der Kwast T, Bristow RG.

Clin Cancer Res. 2012 Jan 1;18(1):308-16. doi: 10.1158/1078-0432.CCR-11-2147. Epub 2011 Nov 2.


PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.

Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA.

Genes Chromosomes Cancer. 2012 Feb;51(2):149-60. doi: 10.1002/gcc.20939. Epub 2011 Nov 1.


Prostate cancer as a model system for genetic diversity in tumors.

Squire JA, Park PC, Yoshimoto M, Alami J, Williams JL, Evans A, Joshua AM.

Adv Cancer Res. 2011;112:183-216. doi: 10.1016/B978-0-12-387688-1.00007-7. Review.


Integrated cytogenetic and high-resolution array CGH analysis of genomic alterations associated with MYCN amplification.

Pandita A, Bayani J, Paderova J, Marrano P, Graham C, Barrett M, Prasad M, Zielenska M, Squire JA.

Cytogenet Genome Res. 2011;134(1):27-39. doi: 10.1159/000324698. Epub 2011 Apr 18.


Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma.

Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA.

Cancer Genet. 2011 Mar;204(3):138-46. doi: 10.1016/j.cancergen.2010.12.012.


Cyclin E1 is amplified and overexpressed in osteosarcoma.

Lockwood WW, Stack D, Morris T, Grehan D, O'Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM, O'Sullivan MJ.

J Mol Diagn. 2011 May;13(3):289-96. doi: 10.1016/j.jmoldx.2010.11.020. Epub 2011 Mar 31.

Supplemental Content

Loading ...
Support Center